Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of SYN818, a DNA Polymerase Theta (POLQ) Inhibitor Alone in Patients With Locally Advanced or Metastatic Solid Tumors

NCT06666270 is registered in ClinicalTrials.gov with Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd as lead sponsor.

NCT NCT06666270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06666270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of SYN818, a DNA Polymerase Theta (POLQ) Inhibitor Alone in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
November 21, 2024
Completion date
December 30, 2026
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid cancer, brca mutation, breast cancer, hrr deficiency, metastatic solid tumor, ovarian cancer, prostate cancer